Public trial registry of the CCC-Munich

Trial RC57, AIO-PK 1004

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
RC57, AIO-PK 1004
World
Full title
:

Capecitabin + Erlotinib gefolgt von Gemcitabin versus Gemcitabin + Erlotinib gefolgt von Capecitabin - randomisierte Phase III Studie zur Behandlung des fortgeschrittenen Pankreaskarzinoms

World
NCT number
:
World
Responsible organization
:
Medizinische Klinik III, Telefon: 089440072551
Indications
Classification Code Description
ICD-10-GM C25.- Bösartige Neubildung des Pankreas
- Pancreas carcinoma
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2012-12-31 / Unknown
Participants
Function Prename Surname Organization
World Principal Investigator VOLKER HEINEMANN Keine Organisationseinheit angegeben Magnifier